KPRX
NASDAQ · Pharmaceuticals
Kiora Pharmaceuticals Inc
$2.48
+0.03 (+1.22%)
Financial Highlights (FY 2026)
Revenue
15.53M
Net Income
3.48M
Gross Margin
—
Profit Margin
22.4%
Rev Growth
+81.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 63.2% | 63.2% |
| Operating Margin | 27.5% | 24.7% | 19.4% | 19.8% |
| Profit Margin | 22.4% | 21.3% | 17.3% | 15.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 15.53M | 8.57M | 1.95M | 2.03M |
| Gross Profit | — | — | 1.23M | 1.28M |
| Operating Income | 4.27M | 2.12M | 377.4K | 401.3K |
| Net Income | 3.48M | 1.73M | 336.4K | 321.2K |
| Gross Margin | — | — | 63.2% | 63.2% |
| Operating Margin | 27.5% | 24.7% | 19.4% | 19.8% |
| Profit Margin | 22.4% | 21.3% | 17.3% | 15.8% |
| Rev Growth | +81.3% | +81.3% | -4.0% | +17.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 2.15M | 2.24M |
| Total Equity | — | — | 2.54M | 2.59M |
| D/E Ratio | — | — | 0.84 | 0.87 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.31M | 2.26M | 564.5K | 565.8K |
| Free Cash Flow | — | — | 437.5K | 326.8K |